Can you get Wegovy with a BMI of 28?

The decision your BMI of 28 actually rests on

Think of your BMI as a threshold, not a verdict. At 28, you sit comfortably inside the lower band of the licensed range for Wegovy, and you can read a full breakdown of how Wegovy works and what to expect from treatment before you go any further. But the licence for that lower band is conditional. Adults with a BMI between 27 and 29.9 must also have at least one weight-related health condition for semaglutide to be appropriate. Without that, the medicine is not licensed for you, and a responsible prescriber will not issue it.

So the real decision point is not your BMI number. It is whether a health condition that sits alongside your weight changes the clinical calculation. Common qualifying conditions include type 2 diabetes or prediabetes, hypertension, raised cholesterol or triglycerides, obstructive sleep apnoea, and established cardiovascular disease. Osteoarthritis linked to weight can also be relevant in some assessments. If you live with any of these, your BMI of 28 may well be enough to reach the eligibility threshold, and that is what the prescriber is weighing up.

One thing worth keeping in mind: if your ethnic background is South Asian, Chinese, Middle Eastern, Black African or African-Caribbean, UK clinical guidance applies a BMI adjustment of 2.5 kg/m² downward. That does not change the requirement for a comorbidity, but it does mean the thresholds are read slightly differently for you. Our full guide to BMI requirements for Wegovy covers how those adjustments work in practice.

What the prescriber looks at beyond the number on your scales

A prescriber reviewing your consultation does not stop at the BMI. They are assessing the whole picture: your current health conditions and how well controlled they are, any medicines you already take, your medical history, and whether there are reasons Wegovy would not be suitable. Contraindications include a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, active pancreatitis, and certain gastrointestinal conditions, all of which are explored during the consultation.

Pregnancy, breastfeeding and actively trying to conceive are all situations in which Wegovy is not recommended. The same applies to anyone under 18. These are not administrative boxes; they reflect real clinical risk, and a prescriber takes them seriously regardless of what your BMI is.

There is also a practical point about what the evidence shows. The clinical trials that established Wegovy's effectiveness (including the STEP 1 study, published in the New England Journal of Medicine, which followed adults for 68 weeks and found an average weight reduction of around 15%) enrolled people with BMI 30 and above, or 27 and above with a comorbidity. That framing directly mirrors the licensed criteria. It matters because a BMI of 28 with a qualifying condition is the population the research actually studied.

If you are uncertain whether your conditions would qualify, our prescribers are the right people to ask. You can also read about how different BMI levels affect eligibility on the guide to BMI thresholds for taking Wegovy.

How Wegovy access at BMI 28 differs on the NHS versus privately

On the NHS, Wegovy is available only through specialist weight management services, under the NICE recommendation set out in TA875. Those criteria are more restrictive than the licence: NICE recommends Wegovy for adults with a BMI of 35 or above (or 30 and above with qualifying criteria), within a multidisciplinary programme, for a maximum of two years. At BMI 28, NHS access under TA875 is not available, the threshold simply is not met.

A private prescription is a different route. The licensed criteria, rather than the narrower NICE NHS criteria, apply. That means a BMI of 28 with a weight-related condition can, in principle, be within scope for a private prescription, subject to clinical assessment. Waiting lists and referral requirements do not apply; the assessment and prescription happen directly through the prescribing service.

On cost: private Wegovy treatment is priced per month, and the total varies by dose and provider. Understanding what is included in a quoted price matters. Some quotes cover the medicine only; others fold in the consultation, prescription and aftercare. For a fuller picture of how private pricing works, the weight-loss treatment overview is a useful starting point. A genuine clinical service will never discount a prescription-only medicine as a promotional offer, that is a reliable red flag when comparing providers.

If you are between a BMI of 27 and 30, our guide to Wegovy eligibility at BMI 26 can help frame exactly where you sit in relation to the licensed thresholds, alongside the BMI 30 eligibility comparison. At 28, you are in the conditional zone, the health history is what tips the balance. If you are also wondering whether someone with a BMI of 25 could ever qualify, our guide to Wegovy eligibility at BMI 25 explains where that lower boundary sits and why the comorbidity requirement becomes even more significant at that point. At nume we have a clinical team who handle these questions every week. The honest answer is that a short consultation is the only way to know for certain whether the criteria fit your situation.

Starting a conversation with a prescriber

A BMI of 28 with a qualifying health condition is not a borderline that calls for anxiety, it is a clinical picture that a prescriber can read clearly. What the consultation does is confirm the details: which conditions are present and documented, what other treatments you may have tried, and whether there are any clinical reasons to proceed differently.

At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber. No part of the clinical assessment is handled by an algorithm. If you order before noon on a working day, the review happens the same day; treatment is dispatched that afternoon if approved, and DPD delivers it free the next working day in plain, unbranded packaging. There are no subscriptions, every repeat order gets its own clinical review.

You can verify nume's pharmacy registration (GPhC premises number 9012878) directly at the GPhC register. If you want to understand more about the team behind the clinical decisions, the clinical profile is there to read. When you are ready, speak to our prescribers, a free consultation is the right next step.